Journal of Bioequivalence & Bioavailability

Glipizide pharmacokinetics in healthy and diabetic volunteers

2^nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit-2011 and International Conference on Pharmaceutics & Novel Drug Delivery Systems

06-08 June 2011, Las Vegas, USA

Muhammad Atif, Syed Azhar Syed Sulaiman, Asrul Akmal Shafi e

Scientific Tracks Abstracts: JBB

Abstract:

Purpose: Disease state may contribute to alteration on drug pharmacokinetics. Th e purpose of this study was to determine the eff ect of non-insulin dependent diabetes mellitus (NIDDM) on the pharmacokinetics of glipizide. Method: An open, single-dose, parallel design was applied to the study. Glipizide tablet (5 mg) was administered to healthy and diabetic human volunteers aft er over- night fast. Blood samples were collected, centrifuged and the plasma assayed using a sensitive and validated reverse phase high performance liquid chromatography (RP- HPLC) method. Various pharmacokinetic parameters were computed from the data obtained. Results: Th e AUC 0-∞ values for healthy and diabetic volunteers was 1878?195 and 1723?138 ng.h/ml respectively; these values were not signifi cantly diff erent (p > 0.05). Th e t 1/2 for healthy volunteers was 3.04?0.27 h while that for diabetic subjects was 2.98?0.16 h. Clearance for healthy and diabetic volunteers was 0.59?0.06 and 0.64?0.05 ml/min/kg, respectively. All the foregoing and other pharmacokinetic parameters assessed not signifi cantly diff erent when compared for healthy and diabetic volunteers (p > 0.05). Conclusion: Although glipizide showed slightly more rapid clearance from the body of diabetic volunteers than from healthy volunteers, this diff erence, like those for other pharmacokinetic parameters, was not signifi cant (p > 0.05).